Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biomarkers in Oncology | Access & Reimbursement | US | Malignant Melanoma, Colorectal Cancer, Ovarian Cancer | US

Login to access report north_east
Contact sales account_box

Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant melanoma, colorectal cancer, and ovarian cancer. When incorporated into standard clinical care, biomarker-driven therapies offer specific subpopulations of patients the potential for higher response rates and improved survival, albeit often at a high price. We explore the drivers of and barriers to the use of biomarker-based therapies and the impact of reimbursement policies on the use of these therapies. We also evaluate surveyed medical oncologists’ and surveyed payers’ prescriptions of emerging biomarker-driven therapies to treat these solid-tumor indications.

 

QUESTIONS ANSWERED

· What factors largely influence payers’ reimbursement decisions for biomarker-driven therapies in malignant melanoma, colorectal cancer, and ovarian cancer? What restrictions do they impose?

· Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?

· What impact do reimbursement and access have on oncologists’ decisions to prescribe biomarker-driven therapies?

· What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?

 

GEOGRAPHY: United States.

PRIMARY RESEARCH: Survey of 101 U.S. medical oncologists and 31 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).

KEY DRUGS COVERED: Avastin, Erbitux, Vectibix, Opdivo, Keytruda, Yervoy, Zelboraf, Tafinlar, Mekinist, Cotellic, Braftovi, Mektovi, Lynparza, Zejula, Rubraca

CONTENT HIGHLIGHTS:

  • Executive Summary
  • Reimbursement
  • Access and prescribing.
  • Special topic: Market Access Outlook for biomarkers testing
  • Opportunities and challenges for emerging therapies.
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east